FOLH1 and prostate cancer: Controls for antibody performance were included with every experiment using two prostate cancer cell lines expressing different levels of PSMA and EpCAM (C4-2:PSMA+/EpCAM+/CD45− and PC3: PSMA−/EpCAM−/CD45−) and the CD45+ leukemia cell line U937 (Figure S1A).